Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Graft-versus-host Disease (GvHD)
72%
Acute Myeloid Leukemia
38%
Hematopoietic Stem Cell Transplantation
29%
Overall Survival
25%
Hematopoietic Cell Transplantation
23%
Confidence Interval
23%
Non-relapse Mortality
18%
Progression-free Survival
17%
Reduced-intensity Conditioning
16%
Transplantation
14%
Diffuse Large B-cell Lymphoma (DLBCL)
14%
Allogeneic Transplantation
13%
Myelodysplastic Syndrome
13%
Hematological Malignancies
12%
Hazard Ratio
12%
Phase II Trial
12%
Cyclophosphamide
12%
Marrow Transplantation
11%
Busulfan
11%
Lymphoma
10%
Non-Hodgkin Lymphoma
9%
High Risk
9%
Relapsed or Refractory
9%
Quality of Life
9%
First Complete Remission
9%
FMS-like Tyrosine Kinase 3 (FLT3)
9%
Unrelated Donor
8%
Umbilical Cord Blood Transplantation
8%
Maintenance Therapy
8%
Reduced Intensity
8%
High-dose Chemotherapy
8%
Tyrosine Kinase Inhibitor
7%
Isocitrate Dehydrogenase 1 (IDH1)
7%
Minimal Residual Disease
7%
Phase II Study
7%
Double Umbilical Cord Blood
7%
Rituximab
6%
Mount Sinai
6%
Clinical Trials
6%
Graft-versus-host Disease Prophylaxis
6%
International Consortium
6%
Corticosteroids
6%
Pretransplant
6%
Allogeneic HSCT
6%
Risk Factors
6%
Phase 1 Study
6%
Lymphoma Patients
6%
Thiotepa
6%
Myeloablative Conditioning
5%
Medicine and Dentistry
Hematopoietic Cell
58%
Cell Transplantation
50%
Transplantation
42%
Acute Myeloid Leukemia
36%
Hematopoietic Stem Cell Transplantation
30%
Graft Versus Host Reaction
30%
Acute Graft Versus Host Disease
23%
Overall Survival
23%
Autologous Stem Cell Transplantation
22%
Allogeneic Hematopoietic Stem Cell Transplantation
20%
Diseases
19%
Progression Free Survival
17%
Diffuse Large B-Cell Lymphoma
14%
Quality of Life
13%
Chronic Graft Versus Host Disease
13%
Allograft
12%
Reduced Intensity Conditioning
11%
Myelodysplastic Syndrome
11%
Allogeneic Stem Cell Transplantation
11%
Cyclophosphamide
11%
Clinical Trial
10%
Non-Hodgkin Lymphoma
10%
Hematologic Malignancy
10%
Hazard Ratio
10%
Maintenance Therapy
9%
Cord Blood
9%
Minimal Residual Disease
8%
Busulfan
8%
Tyrosine-Kinase Inhibitor
6%
Biological Marker
6%
Central Nervous System
6%
High Dose Chemotherapy
6%
Randomized Clinical Trial
6%
Placebo
5%
Cumulative Incidence
5%
Leukemia
5%
T Cell
5%
Malignant Neoplasm
5%
Prophylaxis
5%
Kidney Transplantation
5%
Bone Marrow Transplantation
5%
Pembrolizumab
5%
Immunology and Microbiology
Graft-Versus-Host Disease
53%
Hematopoietic Cell
47%
Acute Graft Versus Host Disease
44%
Cell Transplantation
44%
Overall Survival
21%
Myeloid
21%
Hematopoietic Stem Cell Transplantation
19%
Conditioning
19%
Allogeneic Hematopoietic Stem Cell Transplantation
17%
Autologous Stem Cell Transplantation
16%
Allogeneic Stem Cell Transplantation
14%
Progression Free Survival
14%
Chronic Graft Versus Host Disease
13%
Cyclophosphamide
13%
Umbilical Cord Blood
13%
Drug Megadose
11%
Allograft
11%
B Cell
9%
Cord Blood Stem Cell Transplantation
7%
Central Nervous System
7%
T Cell
6%
Bone Marrow Transplantation
6%
Tacrolimus
6%
Allele
6%
Vedolizumab
6%
Regulatory T Cell
6%
Feces microflora
5%
Rituximab
5%